Literature DB >> 6508330

Response of mycosis fungoides to topical chemotherapy with mechlorethamine.

D L Ramsay, R E Parnes, N Dubin.   

Abstract

Seventy-six patients with mycosis fungoides (MF) were given topical mechlorethamine hydrochloride therapy. Allergic contact hypersensitivity reactions to the drug developed in 51 patients (67.1%). Sixty-four patients of the original 76 continued therapy, with 43 (67.2%) achieving a complete remission and 12 (18.8%) achieving a partial remission. Stage I disease responded significantly better than did subsequent, more severe disease stages. The median times to complete remission were 5.6 months, 32.3 months, and 22.3 months for stage I, II, and III disease, respectively. The conditions of patients with contact sensitivity did not respond better than those of patients without contact sensitivity. Patients with substage A disease did not respond better patients with substage B disease. These findings are encouraging and indicate that the use of topically applied mechlorethamine for early-stage MF should be continued, despite the development of contact dermatitis to the drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6508330

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  6 in total

1.  Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.

Authors:  Stuart R Lessin; Madeleine Duvic; Joan Guitart; Amit G Pandya; Bruce E Strober; Elise A Olsen; Christopher M Hull; Elizabeth H Knobler; Alain H Rook; Ellen J Kim; Mark F Naylor; David M Adelson; Alexa B Kimball; Gary S Wood; Uma Sundram; Hong Wu; Youn H Kim
Journal:  JAMA Dermatol       Date:  2013-01       Impact factor: 10.282

Review 2.  Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data.

Authors:  Kendall Liner; Celeste Brown; Laura Y McGirt
Journal:  Drug Des Devel Ther       Date:  2018-01-31       Impact factor: 4.162

3.  Chlormethine Gel in Combination with Other Therapies in the Treatment of Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: Three Case Reports.

Authors:  Kyriaki Lampadaki; Marios Koumourtzis; Fani Karagianni; Leonidas Marinos; Evangelia Papadavid
Journal:  Adv Ther       Date:  2021-04-30       Impact factor: 3.845

Review 4.  Chlormethine Gel for the Treatment of Skin Lesions in All Stages of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Narrative Review and International Experience.

Authors:  Larisa J Geskin; Martine Bagot; Emmilia Hodak; Ellen J Kim
Journal:  Dermatol Ther (Heidelb)       Date:  2021-05-21

5.  Randomized Mechlorethamine/Chlormethine Induced Dermatitis Assessment Study (MIDAS) Establishes Benefit of Topical Triamcinolone 0.1% Ointment Cotreatment in Mycosis Fungoides.

Authors:  Carolina V Alexander-Savino; Catherine G Chung; Elaine S Gilmore; Sean M Carroll; Brian Poligone
Journal:  Dermatol Ther (Heidelb)       Date:  2022-02-05

Review 6.  Chlormethine Gel for Patients with Mycosis Fungoides Cutaneous T Cell Lymphoma: A Review of Efficacy and Safety in Clinical Trial and Real-World Settings.

Authors:  Ulrike Wehkamp; Marco Ardigò; Evangelia Papadavid; Christiane Querfeld; Neda Nikbakht
Journal:  Adv Ther       Date:  2022-07-19       Impact factor: 4.070

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.